2J·

Viking Therapeutics reported earnings Q1 FY2025 results ended on Mar 31, 2025

- Net loss: $45.6M or ($0.41)/share vs $27.4M or ($0.26)/share in Q1 2024

- R&D expense: $41.4M, +72% YoY

- Cash & equivalents: $852M vs $903M as of Dec 31, 2024

CEO Brian Lian: "We continued to ramp up activities in support of the initiation of Phase 3 trials with the subcutaneous formulation of VK2735... and completed enrollment in our Phase 2 oral dosing trial."

🌱Revenue & Growth

- Revenue: $0 (no revenue reported, clinical-stage company)

- No commercial products; pipeline in clinical development stages

💰Profits & Health

- Net loss: $45.6M vs $27.4M in Q1 2024

- R&D: $41.4M vs $24.1M in Q1 2024

- G&A: $14.1M vs $10.0M in Q1 2024

- Interest income: $9.9M vs $6.7M in Q1 2024

- Cash, cash equivalents & short-term investments: $852M

- Shares outstanding: 112.1M

📌Business Highlights

- Phase 2 VENTURE-Oral trial (13-week dosing) fully enrolled (~280 subjects)

- Phase 3 trials for SC VK2735 in obesity to begin Q2 2025

- DACRA program advancing; IND filing expected 2H25

- Manufacturing agreement signed with CordenPharma for VK2735 API + fill/finish

- Strong cash runway supports pipeline development

🔮Future Outlook

- VENTURE-Oral data readout expected in 2H25

- Phase 3 VK2735 SC trials to start Q2 2025

- IND submission for DACRA program in 2H25

- Continued R&D investment to support VK2735, VK2809, VK0214 development

5

Aktien Stammtisch

@Aktien_Stammtisch

2Mo·

Viking Therapeutics reported earnings Q4 FY2024 results ended on December 31, 2024

$VKTX (-2 %)

- R&D expenses: $31.0M, +51% YoY

- Net loss: $35.4M vs $24.6M YoY

- Strong cash position: $903M vs $362M YoY

CEO Brian Lian: "2024 was an exciting and extremely productive year for Viking. During the year, the company reported positive data from four different clinical trials, including results from the Phase 2 VENTURE study of subcutaneous VK2735 for obesity, the Phase 1 study of an oral tablet formulation of VK2735 for obesity, the Phase 2b VOYAGE study of VK2809 for MASH and fibrosis, and the Phase 1b study of VK0214 for X-ALD."

🌱Revenue & Growth

- No revenue reported in Q4 2024 and Q4 2023

- R&D expenses: $31.0M vs $20.5M in Q4 2023

- G&A expenses: $15.3M vs $8.8M in Q4 2023

💰Profits & Financials

- Q4 Net loss: $35.4M ($0.32/share) vs $24.6M ($0.25/share) YoY

- FY2024 Net loss: $110.0M ($1.01/share) vs $85.9M ($0.91/share) YoY

- Cash and investments: $903M as of Dec 31, 2024

- Interest income: $10.8M vs $4.7M in Q4 2023

📌Business Highlights

- Completed Phase 2 VENTURE study of VK2735 for obesity with up to 14.7% weight loss

- Initiated Phase 2a VENTURE-Oral Dosing trial for oral VK2735

- Reported positive Phase 1b results for VK0214 in X-ALD treatment

🔮Future Outlook

- Phase 3 studies for subcutaneous VK2735 planned for Q2 2025

- Phase 2 VENTURE-Oral data expected in 2H 2025

- Plans to file IND for DACRA program in 2025

- Upcoming investor conferences in February-April 2025

6

TaxesAreTheft

@TaxesAreTheft

3Mo·

Sale of Viking

I no longer want to have any "event bets" in my main portfolio. It also no longer fits in with my long-term investment strategy. Now that a stock in my watchlist has been punished properly, I have taken the opportunity to invest the freed-up capital there.

I am still bullish as far as $VKTX (-2 %) so I will build up a position in my trading portfolio again.

22.01

Viking Therapeutics

Vendu à 31,90 €

3

2 Commentaires

Sandy@DividendenMieze

3Mo

I am also invested there, but am still holding

•

1

•

Afficher la réponse

Aktien Stammtisch

@Aktien_Stammtisch

4Mo·

$AMGN (+0,76 %) MariTide demonstrated up to ~20% average weight loss at 52 weeks without a weight loss plateau in people living with obesity or overweight (Amgen Inc)

- Positive data at 52 weeks in a double-blind, dose-ranging Phase 2 study with MariTide (maridebart cafraglutide, formerly AMG 133), an investigational antibody peptide conjugate subcutaneously administered monthly or less frequently. In people living with obesity or overweight without Type 2 diabetes, MariTide demonstrated up to ~20% average weight loss at week 52 without a weight loss plateau, indicating the potential for further weight loss beyond 52 weeks. The study also showed people living with obesity or overweight and Type 2 diabetes, who typically lose less weight on GLP-1 therapies, achieved up to ~17% average weight loss, also without a weight loss plateau, and lowered their average hemoglobin A1C (HbA1c) by up to 2.2 percentage points at week 52. In summary, in both study populations, a weight loss plateau was not observed, again indicating the potential for further weight loss beyond 52 weeks.

- MariTide also demonstrated robust and clinically meaningful improvements in cardiometabolic parameters, including blood pressure, triglycerides and high-sensitivity C-reactive protein (hs-CRP) across doses. There were no significant increases in free fatty acids.

Wall Street was expecting a 25% weight loss result.

$NVO (-0,55 %)
$LLY (+2,83 %) and possibly $VKTX (-2 %) dodged another bullet with $AMGN obesity results disappointing

4

2 Commentaires

Matthias@Rebellion81

4Mo

Increase savings plan. :)

•

1

•

Timon W

@Manchkeiner

5Mo·

$VKTX (-2 %) Is this a good time to get in or build up the position? The product seems to be very good.

2

2 Commentaires

Utilisateur supprimé

5Mo

Le commentaire a été supprimé

Afficher la réponse

TaxesAreTheft

@TaxesAreTheft

5Mo·

$VKTX (-2 %)
Oral VK-2735 side effects + comparison

TaxesAreTheft

@TaxesAreTheft

5Mo·

VK2735 with excellent results

VK2735 (weight loss pill) from Viking Therapeutics $VKTX (-2 %) delivers. At a dose of 100mg, testers lost an average of 8.2% of their body weight over 28 days. VK2735 is not only very effective but also well tolerated.

3

1 Commentaire

Gomerdoc@Gomerdoc

5Mo

The company's turnover at the end of the last financial year was "USD 0.00 million2 with a profit of USD -85.90 million. However, the current market capitalization is USD 7.50 billion! This is a clunker. Either they die from the costs of the phase 3 trials, and only the phase 3 trials count, or they are swallowed up. By the way: With CapriSegna, Novo already has the answer to small players like Viking Therapeutics up its sleeve. Amgen brings MariTide, and Amgen usually buys troublesome competitors out of its protocash, see Horizon Therapeutics.

••

TaxesAreTheft

@TaxesAreTheft

5Mo·

I assume that if $LLY (+2,83 %) and $NOVO B (-0,7 %) do not follow suit $VKTX (-2 %) will become the new market leader.

It could even be that Viking will be the only provider of an effective and well-tolerated weight loss pill for a long time.

Viking is very likely to bring the next two really big blockbuster drugs onto the market. Since the market has been waiting for such blockbusters for a long time, the valuation will be correspondingly high.

Should the share price fall again, take a look at all the GLP-1 pipelines and Viking.

TaxesAreTheft

@TaxesAreTheft

5Mo·

VK2735 with excellent results

VK2735 (weight loss pill) from Viking Therapeutics $VKTX (-2 %) delivers. At a dose of 100mg, testers lost an average of 8.2% of their body weight over 28 days. VK2735 is not only very effective but also well tolerated.

6

10 Commentaires

András A.@Spinat

5Mo

The first is an SC injection, phase 2 study, the second is orally administered product and only the phase 1 study (phase 2 planned). Why do you think these products will replace the products already on the market?

•

3

•

Voir toutes les 8 autres réponses

TaxesAreTheft

@TaxesAreTheft

5Mo·

VK2735 with excellent results

VK2735 (weight loss pill) from Viking Therapeutics $VKTX (-2 %) delivers. At a dose of 100mg, testers lost an average of 8.2% of their body weight over 28 days. VK2735 is not only very effective but also well tolerated.